SEAPORT THERAP. DL-,0001

Seaport Therapeutics showcased its Glyph prodrug platform at the Citigroup conference, highlighting early positive Phase I data for GlyphAllo and GlyphAgo and sufficient post-IPO financing to support key milestones through 2027/2028. GlyphAllo (Phase IIb) targets major depressive disorders with top-line data expected in H1 2027; GlyphAgo (Phase II) demonstrated a 6.8-fold higher oral bioavailability and is slated to deliver further data in 2028. A preclinical Glyph2BLSD program is intended to enable first-in-human studies by the end of 2027; management emphasized improved study quality, IP generation per molecule and potential licensing interest from other pharma companies. » More on de.investing.com

Seaport Therapeutics reported a loss per share of $0.28 for the quarter ended June 30, 2026, unchanged from the same quarter a year earlier. No further financial details were disclosed in the report. » More on finanzen.net

Seaport Therapeutics reported a loss per share of $0.25 for the quarter ended March 31, 2026, unchanged from the year-ago quarter. No further financial details were highlighted in the statement. » More on finanzen.net

Seaport Therapeutics published positive phase‑1 data on GlyphAgo (SPT‑320) in 174 healthy volunteers evaluating safety, tolerability and pharmacokinetics. Across all dose levels there were no serious or liver‑related adverse events and no clinically significant changes in liver parameters. GlyphAgo achieved therapeutic agomelatine levels, showed a 6.8‑fold increase in bioavailability versus unmodified agomelatine and a tenfold lower pharmacokinetic variability. Seaport plans a phase‑2a in H2 2026 for generalized anxiety disorder with sleep disturbance and a phase‑2b starting in H1 2027; topline results are expected in early and late 2028, respectively. » More on de.investing.com